ストックスクリーナーアプリを入手
4.98
1.63%
0.08
アフターアワーズ：
4.98
前日終値:
$4.90
開ける：
$5.07
24時間の取引高:
202.89K
Relative Volume:
0.48
時価総額：
$347.14M
収益：
$72.52M
当期純損益:
$-219.77M
株価収益率:
-1.5694
EPS:
-3.1731
ネットキャッシュフロー:
$-252.61M
1週間 パフォーマンス:
+1.63%
1か月 パフォーマンス:
-4.23%
6か月 パフォーマンス:
-39.71%
1年 パフォーマンス:
-21.94%
1日の値動き範囲:
$4.95
$5.135
1週間の範囲:
$4.745
$5.135
52週間の値動き範囲:
$4.24
$9.5499
Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile
名前
Bicycle Therapeutics Plc Adr
セクター
電話
011441223261503
住所
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE
Compare BCYC vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BCYC
Bicycle Therapeutics Plc Adr
|
4.98 | 341.56M | 72.52M | -219.77M | -252.61M | -3.1731 |
VRTX
Vertex Pharmaceuticals Inc
|
443.92 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
775.53 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
785.07 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
327.25 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.19 | 33.72B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-24 | 開始されました | Truist | Hold |
| 2025-10-31 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-08 | 開始されました | Stephens | Equal-Weight |
| 2024-09-06 | 開始されました | RBC Capital Mkts | Outperform |
| 2024-08-07 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2023-09-11 | アップグレード | B. Riley Securities | Neutral → Buy |
| 2022-08-31 | 開始されました | Cowen | Outperform |
| 2022-07-28 | 開始されました | Barclays | Overweight |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-04-13 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2022-04-07 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-02-14 | 開始されました | Morgan Stanley | Equal-Weight |
| 2021-12-17 | 開始されました | SVB Leerink | Outperform |
| 2021-12-09 | 開始されました | Needham | Buy |
| 2021-09-30 | 開始されました | B. Riley Securities | Buy |
| 2021-04-20 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-10-12 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-06-12 | 開始されました | Oppenheimer | Outperform |
| 2020-04-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-11-14 | 開始されました | ROTH Capital | Buy |
| 2019-09-11 | アップグレード | Goldman | Neutral → Buy |
| 2019-06-17 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-17 | 開始されました | Goldman | Neutral |
| 2019-06-17 | 開始されました | Jefferies | Buy |
| 2019-06-17 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Bicycle Therapeutics Plc Adr (BCYC) 最新ニュース
Bicycle Therapeutics (NASDAQ:BCYC) CEO Kevin Lee Sells 5,967 Shares of Stock - MarketBeat
Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Analysts - marketbeat.com
Bicycle Therapeutics (BCYC) proxy: June 17 AGM, board and pay votes (BCYC) - stocktitan.net
After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Bicycle Therapeutics (BCYC) - Yahoo Finance
Bicycle Therapeutics (BCYC) loses 19.0% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Bicycle Therapeutics (BCYC) Drops 19.0% Over the Past 4 Weeks, Reasons a Potential Turnaround Could Be Near - Bitget
Bicycle Therapeutics (BCYC) Loses 19.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
Bicycle Therapeutics (NASDAQ:BCYC) Given New $15.00 Price Target at Needham & Company LLC - Defense World
Bicycle Therapeutics (NASDAQ:BCYC) Given New $36.00 Price Target at Oppenheimer - Defense World
Bicycle Therapeutics stock price target lowered to $7 by RBC Capital - Investing.com South Africa
Citizens cuts Bicycle Therapeutics stock price target on strategic shift By Investing.com - Investing.com South Africa
Truist cuts Bicycle Therapeutics stock price target on pipeline shift By Investing.com - Investing.com South Africa
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift By Investing.com - Investing.com India
Morgan Stanley reiterates Bicycle Therapeutics stock rating on program shift - Investing.com
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
SUNation Energy Inc. (NASDAQ:SUNE) Short Interest Update - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Merit Medical Systems, Inc. (NASDAQ:MMSI) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Principal Financial Group Inc. Grows Position in Bicycle Therapeutics PLC Sponsored ADR $BCYC - MarketBeat
Bicycle Therapeutics (NASDAQ:BCYC) Trading Down 2.6%Time to Sell? - MarketBeat
Bicycle Therapeutics announces leadership changes for next phase By Investing.com - Investing.com South Africa
Bicycle Therapeutics announces leadership changes for next phase - Investing.com
Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline - ChartMill
Comparing Golden Heaven Group (NASDAQ:GDHG) and AiRWA (NASDAQ:YYAI) - Defense World
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com South Africa
Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 - ChartMill
Bicycle Therapeutics (NASDAQ:BCYC) CEO Sells $70,210.00 in Stock - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Shareholders to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Operating cash flow per share of Bicycle Therapeutics Plc Sponsored ADR – FWB:50BA - TradingView — Track All Markets
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
2025-12-28 | Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Investors to Connect - ACCESS Newswire
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2025-12-24 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Investors to Learn More About the Investigation | NDAQ:BCYC | Press Release - Stockhouse
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Investors to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Reach Out - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Connect - ACCESS Newswire
Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bicycle Therapeutics plcBCYC - WV News
Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Bicycle Therapeutics Plc Adr (BCYC) 財務データ
収益
当期純利益
現金流量
EPS
1.51%
1.75%
大文字化:
|
ボリューム (24 時間):